Is R2* a New MRI Biomarker for the Progression of Parkinson's Disease? A Longitudinal Follow-Up

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Ulla, Miguel ^a,b   Bonny, Jean Marie ^c   Ouchchane, Lemlih ^a,b   Rieu, Isabelle ^a,b   Claise, Beatrice ^a,b   Durif, Franck ^a,b  

^a UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

^b UNIVERSITÉ CLERMONT AUVERGNE   (France)

^c UR370 QuaPA   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; BASAL GANGLION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE MARKER; FEMALE; FOLLOW UP; HUMAN; IMAGE ANALYSIS; LONGITUDINAL STUDY; MALE; MOTOR DYSFUNCTION; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; PUTAMEN; QUANTITATIVE ANALYSIS; RADIATION MEASUREMENT; SUBSTANTIA NIGRA PARS COMPACTA; SUBSTANTIA NIGRA PARS RETICULATA; TRANSVERSE RELAXATION RATE; AGED; CASE CONTROL STUDY; METABOLISM; MIDDLE AGED; PATHOLOGY; RETICULAR FORMATION; SUBSTANTIA NIGRA;

BIOLOGICAL MARKER; IRON;

AGED; BASAL GANGLIA; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; IRON; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PARKINSON DISEASE; PUTAMEN; RETICULAR FORMATION; SUBSTANTIA NIGRA;

EID: 84874575900     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0057904     Document Type: Article

References (39)

1. Dexter DT, Carayon A, Javoy-Agid F, Agid Y, Wells FR, et al. (1991) Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. Brain 114 (Pt 4): 1953-1975.
2. Bartzokis G, Cummings JL, Markham CH, Marmarelis PZ, Treciokas LJ, et al. (1999) MRI evaluation of brain iron in earlier- and later-onset Parkinson's disease and normal subjects. Magn Reson Imaging 17: 213-222.
3. Baudrexel S, Nurnberger L, Rub U, Seifried C, Klein JC, et al. (2010) Quantitative mapping of T1 and T2* discloses nigral and brainstem pathology in early Parkinson's disease. Neuroimage 51: 512-520.
4. Gorell JM, Ordidge RJ, Brown GG, Deniau JC, Buderer NM, et al. (1995) Increased iron-related MRI contrast in the substantia nigra in Parkinson's disease. Neurology 45: 1138-1143.
5. Martin WR, Wieler M, Gee M, (2008) Midbrain iron content in early Parkinson disease: a potential biomarker of disease status. Neurology 70: 1411-1417.
6. Michaeli S, Oz G, Sorce DJ, Garwood M, Ugurbil K, et al. (2007) Assessment of brain iron and neuronal integrity in patients with Parkinson's disease using novel MRI contrasts. Mov Disord 22: 334-340.
7. Peran P, Cherubini A, Assogna F, Piras F, Quattrocchi C, et al. (2010) Magnetic resonance imaging markers of Parkinson's disease nigrostriatal signature. Brain 133: 3423-3433.
8. Behnke S, Schroeder U, Dillmann U, Buchholz HG, Schreckenberger M, et al. (2009) Hyperechogenicity of the substantia nigra in healthy controls is related to MRI changes and to neuronal loss as determined by F-Dopa PET. Neuroimage 47: 1237-1243.
9. Graham JM, Paley MN, Grunewald RA, Hoggard N, Griffiths PD, (2000) Brain iron deposition in Parkinson's disease imaged using the PRIME magnetic resonance sequence. Brain 123 Pt 12: 2423-2431.
10. Ryvlin P, Broussolle E, Piollet H, Viallet F, Khalfallah Y, et al. (1995) Magnetic resonance imaging evidence of decreased putamenal iron content in idiopathic Parkinson's disease. Arch Neurol 52: 583-588.
11. Wallis LI, Paley MN, Graham JM, Grunewald RA, Wignall EL, et al. (2008) MRI assessment of basal ganglia iron deposition in Parkinson's disease. J Magn Reson Imaging 28: 1061-1067.
12. Kosta P, Argyropoulou MI, Markoula S, Konitsiotis S, (2006) MRI evaluation of the basal ganglia size and iron content in patients with Parkinson's disease. J Neurol 253: 26-32.
13. Bartzokis G, Tishler TA, Lu PH, Villablanca P, Altshuler LL, et al. (2007) Brain ferritin iron may influence age- and gender-related risks of neurodegeneration. Neurobiol Aging 28: 414-423.
14. Hallgren B, Sourander P, (1958) The effect of age on the nonhaem iron in the human brain. J Neurochem 3: 41-51.
15. Martin WR, Roberts TE, Ye FQ, Allen PS, (1998) Increased basal ganglia iron in striatonigral degeneration: in vivo estimation with magnetic resonance. Can J Neurol Sci 25: 44-47.
16. Xu X, Wang Q, Zhang M, (2008) Age, gender, and hemispheric differences in iron deposition in the human brain: an in vivo MRI study. Neuroimage 40: 35-42.
17. Siemonsen S, Finsterbusch J, Matschke J, Lorenzen A, Ding XQ, et al. (2008) Age-dependent normal values of T2* and T2′ in brain parenchyma. AJNR Am J Neuroradiol 29: 950-955.
18. Yablonskiy DA, Haacke EM, (1994) Theory of NMR signal behavior in magnetically inhomogeneous tissues: the static dephasing regime. Magn Reson Med 32: 749-763.
19. Ma J, Wehrli FW, (1996) Method for image-based measurement of the reversible and irreversible contribution to the transverse-relaxation rate. J Magn Reson B 111: 61-69.
20. Gelman N, Gorell JM, Barker PB, Savage RM, Spickler EM, et al. (1999) MR imaging of human brain at 3.0 T: preliminary report on transverse relaxation rates and relation to estimated iron content. Radiology 210: 759-767.
21. Gibb WR, Lees AJ, (1988) The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 51: 745-752.
22. Thobois S, (2006) Proposed dose equivalence for rapid switch between dopamine receptor agonists in Parkinson's disease: a review of the literature. Clin Ther 28: 1-12.
23. Fahn S, Elton RL, and Members of the UPDRS development committee. (1987) Recent Developments in Parkinson's Disease; In S. Fahn CDM, D.B. Calne and M. Goldstein (Eds.), editor. Florham Park (NJ): Macmillan Healthcare Information. 153-163.
24. Eapen M, Zald DH, Gatenby JC, Ding Z, Gore JC, (2011) Using high-resolution MR imaging at 7 T to evaluate the anatomy of the midbrain dopaminergic system. AJNR Am J Neuroradiol 32: 688-694.
25. Du G, Lewis MM, Styner M, Shaffer ML, Sen S, et al. (2011) Combined R2* and diffusion tensor imaging changes in the substantia nigra in Parkinson's disease. Mov Disord 26: 1627-1632.
26. Evans JR, Mason SL, Williams-Gray CH, Foltynie T, Brayne C, et al. (2011) The natural history of treated Parkinson's disease in an incident, community based cohort. J Neurol Neurosurg Psychiatry 82: 1112-1118.
27. Jankovic J, Kapadia AS, (2001) Functional decline in Parkinson disease. Arch Neurol 58: 1611-1615.
28. Bartzokis G, Beckson M, Hance DB, Marx P, Foster JA, et al. (1997) MR evaluation of age-related increase of brain iron in young adult and older normal males. Magn Reson Imaging 15: 29-35.
29. Agid Y, (1991) Parkinson's disease: pathophysiology. Lancet 337: 1321-1324.
30. Gerlach M, Double KL, Youdim MB, Riederer P (2006) Potential sources of increased iron in the substantia nigra of parkinsonian patients. J Neural Transm Suppl: 133-142.
31. Hirsch EC (2006) Altered regulation of iron transport and storage in Parkinson's disease. J Neural Transm Suppl: 201-204.
32. Kortekaas R, Leenders KL, van Oostrom JC, Vaalburg W, Bart J, et al. (2005) Blood-brain barrier dysfunction in parkinsonian midbrain in vivo. Ann Neurol 57: 176-179.
33. Salazar J, Mena N, Hunot S, Prigent A, Alvarez-Fischer D, et al. (2008) Divalent metal transporter 1 (DMT1) contributes to neurodegeneration in animal models of Parkinson's disease. Proc Natl Acad Sci U S A 105: 18578-18583.
34. Connor JR, Boeshore KL, Benkovic SA, Menzies SL, (1994) Isoforms of ferritin have a specific cellular distribution in the brain. J Neurosci Res 37: 461-465.
35. Hirsch EC, Hunot S, (2009) Neuroinflammation in Parkinson's disease: a target for neuroprotection? Lancet Neurol 8: 382-397.
36. Zecca L, Youdim MB, Riederer P, Connor JR, Crichton RR, (2004) Iron, brain ageing and neurodegenerative disorders. Nat Rev Neurosci 5: 863-873.
37. He Y, Thong PS, Lee T, Leong SK, Mao BY, et al. (2003) Dopaminergic cell death precedes iron elevation in MPTP-injected monkeys. Free Radic Biol Med 35: 540-547.
38. Mitsumori F, Watanabe H, Takaya N, (2009) Estimation of brain iron concentration in vivo using a linear relationship between regional iron and apparent transverse relaxation rate of the tissue water at 4.7 T. Magn Reson Med 62: 1326-1330.
39. Punwani S, Cooper CE, Clemence M, Penrice J, Amess P, et al. (1997) Correlation between absolute deoxyhaemoglobin [dHb] measured by near infrared spectroscopy (NIRS) and absolute R2' as determined by magnetic resonance imaging (MRI). Adv Exp Med Biol 413: 129-137.